Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:SRNE NASDAQ:SXTC NASDAQ:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.52$0.52$0.52▼$29.97$1.42MN/A5.06 million shsN/ASRNESorrento Therapeutics$0.00$0.00$0.00▼$0.10$276K0.3300,709 shs144,469 shsSXTCChina SXT Pharmaceuticals$1.55-1.3%$1.83$1.25▼$1,046.99$1.51M1.9620,533 shs5,164 shsUPCUniverse Pharmaceuticals$2.54-1.6%$2.82$2.00▼$11.00$1.45M1.5815,270 shs1,427 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%0.00%0.00%-12.62%-92.43%SRNESorrento Therapeutics-16.67%-28.57%-37.50%-70.59%-54.55%SXTCChina SXT Pharmaceuticals-0.63%-4.85%-21.89%-37.45%-99.13%UPCUniverse Pharmaceuticals-4.62%-2.64%-19.68%-3.73%+257,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.52$0.52$0.52▼$29.97$1.42MN/A5.06 million shsN/ASRNESorrento Therapeutics$0.00$0.00$0.00▼$0.10$276K0.3300,709 shs144,469 shsSXTCChina SXT Pharmaceuticals$1.55-1.3%$1.83$1.25▼$1,046.99$1.51M1.9620,533 shs5,164 shsUPCUniverse Pharmaceuticals$2.54-1.6%$2.82$2.00▼$11.00$1.45M1.5815,270 shs1,427 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%0.00%0.00%-12.62%-92.43%SRNESorrento Therapeutics-16.67%-28.57%-37.50%-70.59%-54.55%SXTCChina SXT Pharmaceuticals-0.63%-4.85%-21.89%-37.45%-99.13%UPCUniverse Pharmaceuticals-4.62%-2.64%-19.68%-3.73%+257,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 1.50ReduceN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ASXTCChina SXT Pharmaceuticals 1.00SellN/AN/AUPCUniverse Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SRNE, SXTC, UPC, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026SXTCChina SXT Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/1/2026UPCUniverse Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbproN/AN/AN/AN/A($8.83) per shareN/ASRNESorrento Therapeutics$60.32M0.00N/AN/AN/A∞SXTCChina SXT Pharmaceuticals$1.74M0.86N/AN/A$3,187.45 per share0.00UPCUniverse Pharmaceuticals$17.86M0.08N/AN/A$99.64 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23M-$4.23N/AN/AN/AN/AN/A-344.76%N/ASRNESorrento Therapeutics-$572.84M-$0.43N/AN/AN/AN/AN/AN/AN/ASXTCChina SXT Pharmaceuticals-$3.30MN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse Pharmaceuticals-$3.67MN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ASXTCChina SXT PharmaceuticalsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.070.07SRNESorrento TherapeuticsN/AN/AN/ASXTCChina SXT PharmaceuticalsN/A4.374.24UPCUniverse PharmaceuticalsN/A4.073.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%SRNESorrento Therapeutics0.02%SXTCChina SXT Pharmaceuticals5.02%UPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipABPAbpro13.70%SRNESorrento Therapeutics2.60%SXTCChina SXT Pharmaceuticals3.95%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro152.72 million2.34 millionN/ASRNESorrento Therapeutics800551.28 million536.95 millionNo DataSXTCChina SXT Pharmaceuticals90960,000925,000Not OptionableUPCUniverse Pharmaceuticals220560,000240,000N/ASRNE, SXTC, UPC, and ABP HeadlinesRecent News About These CompaniesUniverse Pharmaceuticals Incorporation Class AApril 29, 2026 | edition.cnn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% – Time to Sell?April 25, 2026 | defenseworld.netDUniverse Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share StructureFebruary 11, 2026 | tipranks.comUniverse Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026February 11, 2026 | quiverquant.comQUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureFebruary 11, 2026 | globenewswire.comUniverse Pharmaceuticals Inc trading resumesOctober 8, 2025 | msn.comUniverse Pharmaceuticals Inc trading halted, volatility trading pauseOctober 8, 2025 | msn.comUniverse Pharmaceuticals Approves Key Resolutions at 2025 AGMSeptember 3, 2025 | msn.comUniverse Pharmaceuticals Reports Decline in Financial Performance Amid Regulatory ChangesAugust 31, 2025 | theglobeandmail.comUniverse Pharmaceuticals Postpones Annual General Meeting Due to Quorum IssueAugust 26, 2025 | msn.comUniverse Pharmaceuticals Inc. (UPC) Stock Price Today - WSJAugust 7, 2025 | wsj.comPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIs Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Micron Investors Face a High-Stakes Moment After the Latest RallyBy Thomas Hughes | May 13, 2026Storm Warning? Rivian's Real Test Is Not a TornadoBy Jeffrey Neal Johnson | April 22, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026Kinder Morgan’s Cash Flow Drives Upside: Potential Swells in Q1By Thomas Hughes | April 24, 2026SRNE, SXTC, UPC, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.52 0.00 (0.00%) As of 05/18/2026Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Sorrento Therapeutics NASDAQ:SRNE$0.0005 0.00 (0.00%) As of 03:33 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.China SXT Pharmaceuticals NASDAQ:SXTC$1.55 -0.02 (-1.27%) Closing price 03:55 PM EasternExtended Trading$1.52 -0.03 (-1.61%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.Universe Pharmaceuticals NASDAQ:UPC$2.54 -0.04 (-1.55%) Closing price 03:28 PM EasternExtended Trading$2.54 0.00 (0.00%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
